Mar. 19 at 6:49 PM
$BRTX DD detail updated : AI copy DD Research::
.✅️ "OSR" Annual Meeting " 3-28-31 " Discussions:
$PFE During recent business updates, management confirmed they are in active licensing discussions with 2 regenerative medicine partners for the ThermoStem program. BR-100 in Phase 2 trials can be used in 4 states now before final FDA approval..✅️
stockinsights.ai
Licensing Strategy: 👇 ((( The company is positioning these 3+ key patent families to be "off-balance sheet" assets . Meaning
$BRTX will have a partner to fund the expensive clinical trials while BioRestorative. Company retains about 8% royalty and milestone rights total DD of payout up to
$400 million on phase 3 success and FDA approval of drug . Payment of
$35 to
$75 million dollars in cash upfront on exclusive licensing currently in progress. ))) 👇 Metabolic Market Heat: 🔑🔑 Since companies PFIZER
$PFE any Eli Lilly
$LLY are🌞 Desperately seeking "GLP-1 enhancers of
$BRTX ( drugs to keep muscle while losing fat ) " (((
$BRTX ONLY company with the Required Patents in 3+ major countries🌞 to burn brown fat and Not have 20%+ muscle loss with the wanted loss of body fat in near 100 billion dollar market . ))) 🔑 🔑
stockinsights.ai
Summary: While no finalized licensing deal has been signed yet. But recent patent grant in Australia (Feb 24) suggests
$BRTX are very actively polishing details of the "package" while making offers to several active suitors.
🔑 Bullish on OSR showcase meeting for Big Pharma to make deals in licensing , partnering and funding of new patents and early research funding is what this meeting is known to do. .🔑..
